QRX003
CL-QRX003-004
Phase 3 small_molecule active
Quick answer
QRX003 for Netherton Syndrome is a Phase 3 program (small_molecule) at Quoin Pharmaceuticals, with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Quoin Pharmaceuticals,
- Indication
- Netherton Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active